William Bertrand compensation by year
Adaptimmune Therapeutics Summary Compensation Table · all 2 fiscal years held| Component | FY2023 | FY2024 |
|---|---|---|
| Salary | $468,179 | $486,906 |
| Bonus | $0 | — |
| Stock awards | $0 | $0 |
| Option awards | $507,762 | $355,272 |
| Non-equity incentive | $200,147 | $175,286 |
| Pension and deferred compensation | $0 | $0 |
| All other | $39,012 | $40,905 |
| Total | $1,215,100 | $1,058,369 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Adaptimmune Therapeutics PLC DEF 14A filed April 25, 2025, accession 0001104659-25-039042, and prior-year filings.
How this page was built: the Adaptimmune Therapeutics PLC filed document, accession 0001104659-25-039042. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 674,178 | $732,894 | — |
| Option | 235,692 | $0 | $0.00 |
| Option | 60,678 | $0 | $0.00 |
| Option | 565,416 | $0 | $0.00 |
| Option | 157,128 | $0 | $0.00 |
| Option | 2,544,432 | $0 | $0.14 |
| Option | 381,174 | — | $0.55 |
| Option | 22,642 | — | $0.95 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Adaptimmune Therapeutics PLC's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2024 proxy (filed April 25, 2025)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-08-28 | Sale | — | 207,000 | $0.01 | 986,352 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Adaptimmune Therapeutics’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Adrian Rawcliffe | Chief Executive Officer and Director | $2,109,075 |
| Cintia Piccina | Chief Commercial Officer | $1,746,296 |
| William Bertrand · this page | Chief Operating Officer | $1,058,369 |
William Bertrand's compensation dossier, Adaptimmune Therapeutics
You have read William Bertrand's totals and holdings. The dossier adds each equity grant Adaptimmune Therapeutics disclosed for William Bertrand and Adaptimmune Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Adaptimmune Therapeutics compensation record
free company briefThis page is one person within Adaptimmune Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Adaptimmune Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Adaptimmune Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Adaptimmune Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.